Research
FORUM TRANSCRIPT

Medpace Holdings – CRO Asset Evaluation, Competitive Analysis & Strategic Business Scalability Opportunities

  • Public Equity
  • Healthcare
  • North America
PREMIUM

Specialist

Former director at Medpace Holdings Inc

Agenda

  • CRO (contract research organisation) operating environment post the biotech funding slowdown and subsequent impact on Medpace’s (NASQ: MEDP) positioning
  • Service offering analysis across early and late stage clinical trials – DCT (decentralised clinical trial) offerings, C&GT (cell and gene therapy) research, bioanalytical capabilities and oncology and neurology pipeline among many others
  • Competitive landscape for Medpace vs other CROs, noting key points of differentiation such as its one-stop shop offering, science-oriented leadership team and unique partnerships
  • Expectations for Q4 2022 results, focusing on backlog conversion rates, projected revenue growth, customer adoption and new revised guidance
  • Medpace’s 6-12-month growth trajectory, discussing elbow room for potential M&A and capitalisation opportunities

Questions

For access to this and thousands of other Transcripts, request a free trial

Request A Demo